Full-Time

Head of Cardiovascular & Renal Discovery Research

Posted on 4/7/2025

Pfizer

Pfizer

10,001+ employees

Develops and manufactures biopharmaceutical products

Compensation Overview

$204.7k - $341.1k/yr

+ Bonus

Expert

No H1B Sponsorship

Cambridge, MA, USA

Eligible for Relocation Package

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • PhD, MD/PhD or MD with a minimum of 10-15 years research experience leading a research laboratory in academic or industry setting, with a sophisticated understanding of modern cardio-renal disease pathophysiology and underlying biology.
  • A demonstrable record of applying the highest scientific rigor and ethical standards to the conduct of biomedical research.
  • Experience leading or collaborating closely with a clinical group that carries out translation research or drug development studies.
  • Demonstrated excellence in designing, executing and interpreting studies of cardiovascular and/or renal disease biomarkers in nonclinical studies that enable their validation for clinical application.
  • Demonstrated ability to think strategically and creatively while contributing to multiple projects, thrive in a highly collaborative, multi-disciplinary team setting.
  • Strong written/verbal communication skills and ability to effectively collaborate with scientists working in other disciplines are essential.
  • A demonstrated record of scientific achievement, for example through high quality and impactful publications in leading scientific and/or medical journals.
  • Evidence of prior success in colleague mentoring and career development.
Responsibilities
  • Apply scientific and clinical expertise to the identification and validation of new drug candidates in the area of cardiovascular and renal disease.
  • As a member of the RU leadership team, contribute to strategic planning and effective operation of the unit.
  • Maintain a ‘cutting edge’ awareness of scientific and technical developments, human genetics, preclinical to clinical translation and apply these where possible to advance the portfolio programs.
  • Design and conduct studies to increase confidence in human biology for new approaches and targets.
  • Provide strong scientific leadership and experimental guidance from target generation-to-clinical candidate programs for a team of scientists with diverse in vitro, ex vivo and in vivo biological expertise.
  • Partner effectively with multi-functional teams encompassing research (including Integrated Biology team and Chemistry) and development (including early clinical development group).
  • Actively contribute to the external collaborative scientific strategy, e.g., identify and build collaborations and liaise with external scientists.
  • Create an environment that values innovation, leadership, employee development, scientific excellence, urgency and accountability.
  • Present research findings to the scientific community through consistent publication in peer-reviewed journals and presentation of the results at scientific meetings.
  • Ensure that all research/discovery work is conducted with highest quality and in accordance with relevant regulatory, QC, and compliance guidelines.
  • Provide supervision and career development opportunities for team of 20-25 colleagues.
  • Advise leadership on issues of relative value and prioritization of ongoing programs.
  • Actively explore opportunities for novel investments through partnerships with the outside biotech community and new scientific initiatives internally.
Desired Qualifications
  • Drug discovery experience is preferred but not essential.

Pfizer is a biopharmaceutical company that focuses on creating and producing healthcare products, including medicines and vaccines. The company conducts extensive research and development to discover new treatments, which are then manufactured and sold to various clients such as governments, healthcare providers, and patients around the world. Pfizer's products include vaccines, oncology treatments, and other specialized medicines. A notable achievement is its partnership with BioNTech to develop a vaccine for COVID-19, which has played a significant role in addressing the pandemic. Pfizer aims to improve public health by ensuring access to vaccines, especially for underserved populations, and continues to grow its product offerings with new approvals and treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Activist investor Starboard Value's $1B stake may drive strategic changes and increase value.
  • Pfizer's investment in Enara Bio strengthens its position in the immunotherapy market.
  • Backing Promise Bio aligns with Pfizer's strategy to enhance its precision medicine portfolio.

What critics are saying

  • Emerging biotech companies like Trimtech and Normunity could impact Pfizer's market share.
  • Slowdown in COVID-19 vaccine demand poses potential revenue challenges for Pfizer.
  • Activist investor involvement may pressure Pfizer to alter business strategies.

What makes Pfizer unique

  • Pfizer's partnership with BioNTech led to a highly effective COVID-19 vaccine.
  • Pfizer invests in AI disease models, enhancing R&D capabilities and drug discovery.
  • Pfizer's focus on precision medicine diversifies its therapeutic areas and strengthens its portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Finsmes
Mar 5th, 2025
Trimtech Therapeutics Raises $31M in Seed Funding

Trimtech Therapeutics, a Cambridge, UK-based biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, raised $31M in Seed funding

Business Wire
Jan 16th, 2025
Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms

Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The

TechCrunch
Oct 23rd, 2024
Promise Bio exits stealth backed by Pfizer and AstraZeneca | TechCrunch

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.

The Wall Street Journal
Oct 7th, 2024
Exclusive | Activist Starboard Value Takes $1 Billion Stake in Pfizer

The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.

Benzinga
Oct 3rd, 2024
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio's EDAPT® platform is

INACTIVE